Raloxifene's Dual Benefits: Why Is It Overlooked?
Raloxifene (Evista) is a drug approved for osteoporosis and breast cancer prevention, but it has largely fallen out of use due to marketing issues, side effects, and competition from newer medications, despite its dual benefits in reducing breast cancer risk and strengthening bones.